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S U M M A R Y
Background: Dengue surveillance data in India are limited and probably substantially underestimate the
burden of disease. A community-based study was undertaken to assess the prevalence of dengue-
speciﬁc immunoglobulin G (IgG) antibodies in children across India and to examine historical dengue
exposure rates. Potential associations between socio-economic factors and dengue seroprevalence were
also assessed (registered at ctri.nic.in: CTRI/2011/12/002243).
Methods: A convenience sample of 2609 healthy children aged 5–10 years was enrolled; these children
were registered at orwere living in the vicinity of eight centres located at six geographically distinct sites
across India. Blood samples were drawn to test for the presence of dengue IgG antibodies using ELISA.
Serotype-speciﬁc neutralizing antibody titres were measured in dengue IgG-positive children using
dengue plaque reduction neutralization tests. Socio-demographic and household information was
collected using a questionnaire.
Results: Overall, 2558/2609 children had viable samples with laboratory results for dengue IgG. Dengue
IgG seroprevalence across all sites was 59.6% (95% conﬁdence interval 57.7–61.5%): the lowest (23.2%)
was in Kalyani, West Bengal, and the highest (80.1%) was inMumbai. Seroprevalence increased with age.
Multivariate analysis suggested associations with household water storage/supply and type of housing.
Half of the subjects with positive IgG results presented amultitypic proﬁle, indicating previous exposure
to more than one serotype.
Conclusions: The overall dengue seroprevalence suggests that dengue endemicity in India is comparable
to that in highly endemic countries of Southeast Asia. Additional prospective studies are required to fully
quantify the disease burden, in order to support evidence-based policies for dengue prevention and
control in India.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).* Corresponding author. Tel.: +91 9968604242; fax: +91 11 23235574.
E-mail address: gargsuneela@gmail.com (S. Garg).
1 Current afﬁliation for Germano Ferreira: P95 Epidemiology and Pharmacovigilance
http://dx.doi.org/10.1016/j.ijid.2016.10.030
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Services, Heverlee, Belgium.
ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
S. Garg et al. / International Journal of Infectious Diseases 54 (2017) 25–30261. Introduction
Dengue is caused by a mosquito-borne ﬂavivirus that is
endemic in tropical and subtropical countries, including India.1
Sporadic outbreaks have been reported in India for over 200 years.
The scale and severity of two major epidemics in the 1990s
prompted the implementation of a number of strategies to aid the
control and surveillance of dengue. In particular, a passive
surveillance programme and publication of guidelines for dengue
prevention and control was launched as an initiative of the
National Vector Borne Disease Control Programme,2 in collabora-
tion with the existing Integrated Disease Surveillance Programme.
Due to non-speciﬁc and often mild symptoms, dengue is
signiﬁcantly under-reported in nearly all countries. This is
exacerbated in India, where dengue surveillance data are collected
from only approximately 500 sentinel hospitals.3 Studies using
global or extrapolated data have quantiﬁed this under-reporting,
and suggest that the dengue disease burden in India is likely to be
the highest in the world.3,4
Dengue has spread from urban to rural areas of India in recent
decades.2,5 All four virus serotypes – DENV-1 to DENV-4 – have
been documented in India, without a clear geographical distribu-
tion. Areas where serotypes co-circulate are increasing in number
and scale.2 Speciﬁcally, DENV-1, DENV-2, and DENV-4 were
isolated during an outbreak of dengue fever in Vellore in
1963 and all four serotypes were isolated during another outbreak
in the same city in 1968.2 DENV-2 was the predominant serotype
from the early 1970s to 2000, responsible for large epidemics in
1993 and 1996. DENV-3 was the predominant serotype in a
2003 outbreak and co-circulated with DENV-1 in 2006 in Dehli.2
Delhi became hyperendemic for dengue, with all four serotypes
isolated in 2003 and 2006.2 No study to date has taken a nationally
representative view of serotype distribution.
Cross-sectional, population-based, age-stratiﬁed seropreva-
lence data describe historical disease transmission intensity.6,7 A
seroprevalence studywas undertaken to describe the prevalence of
dengue-speciﬁc immunoglobulin G (IgG) antibodies and the
infecting serotype proﬁles of positive samples, in children from
eight sites across India.
2. Methods
2.1. Study design and centres
This was a community-based, descriptive, cross-sectional
seroprevalence study and was conducted between January
2011 and October 2012 in healthy children (registered at
ctri.nic.in: CTRI/2011/12/002243). A convenience sample of eight
private or government medical colleges at six geographically
distinct locations was selected (1) to provide a wide geographical
distribution across India, (2) to represent rural and peri-urban
areas, and (3) based on the recognized ability of the site to conduct
epidemiological research. Overall, two sites were selected in New
Delhi and Hyderabad, and one site each in Kalyani, Wardha,
Mumbai, and Bangalore.
This studywas conducted in accordancewith the latest revision
of the Declaration of Helsinki (Seoul, Korea, October 2008),
guidelines for Good Epidemiological Practice,8 and local regulatory
requirements. The study protocol was approved by ethics
committees at the study centres and by the Health Ministry
Steering Committee (HMSC) of the Government of India.
2.2. Participants
Children, 5–10 years old, who were resident at the study sites,
were eligible. This is an age at which blood sample collection isrelatively straightforward. Furthermore, seroconversion, and thus
the demonstration of age-speciﬁc variation in seroprevalence, was
considered likely in this age group. Parents or legal guardians were
invited to enrol children during routine household visits by
community health workers. Written informed consent was
obtained from the parents or legal guardians, and children aged
8–10 years also signed an assent form. Enrolment at the two sites
in Hyderabad was school-based; parent–teacher meetings were
held at randomly selected schools to explain the purpose of the
study, and all eligible children at those schools were invited to
participate. Permission was obtained from the District Education
Ofﬁcer to perform study visits, complete questionnaires, and
collect blood samples from study participants on the premises of
each school.
Assuming a dengue seroprevalence of 30%, a sample size of
323 participants at each site was calculated to ensure a precision of
5% for the two-sided 95% conﬁdence interval (CI) around the
seroprevalence point estimate.
2.3. Data and sample collection
Socio-demographic data (participant’s demographic character-
istics, household occupancy, water supply/storage, self-reported
history of dengue or Japanese encephalitis (JE) virus infection, and
education levels attained by the parents/guardians) were collected
using a questionnaire. The questionnaire was administered by the
health worker through interviewswith the participant’s parents or
legal guardians during the ﬁrst visit. Participants were asked to
report to the afﬁliated centre for blood sample collection (5 ml) by
a trained laboratory technician. The participant’s height and
weightwere recorded using standardmethods. Signiﬁcantmedical
history, current or previous medical conditions, concomitant
medication, recent vaccinations, and reasons for refusal of blood
sampling, where relevant, were recorded.
Blood samples were left at room temperature for 1–2 h before
centrifugation. Each serum sample was divided into aliquots and
stored in 3-ml cryotubes: 0.5 ml for dengue IgG antibody
assessment, 1 ml for dengue plaque reduction neutralization tests
(PRNT), and 0.5 ml for JE IgG antibody detection. Serum samples
were kept frozen at 20 8C or below until analysis.
2.4. Assays
Samples were sent to the Microbiology Department of the
Maulana Azad Medical College (New Delhi) for analysis. Dengue
IgG antibody levels were assessed using commercially available
ELISA kits. The EL1500G kit (Focus Diagnostics, California, USA)
was used for samples from the ﬁrst two sites (New Delhi);
however, due to supply issues, the E-DEN 10G kit (Panbio
Diagnostics, Brisbane, Australia) was used for the other sites. A
sensitivity analysis of the two dengue IgG-speciﬁc ELISA kits
performed on 30 samples conﬁrmed 100% concordance; data from
all centres were thus pooled. JE IgG antibody testing by indirect
ELISA was also performed using commercially available kits
(InBios, Washington, USA). Dengue IgG-positive samples were
sent to the Centre for Vaccine Development (Mahidol University,
Thailand) for measurement of dengue serotype-speciﬁc neutraliz-
ing antibody titres using PRNT based on 50% or greater reduction in
plaque counts (PRNT50).
9
Seropositivity for dengue and JE were deﬁned according to the
manufacturer’s instructions. Seroprevalence was the percentage of
seropositive participants.
For the interpretation of PRNT50 titres, participants were
classiﬁed as follows: ‘naı¨ve’, if antibody titres were <10 (1/dil)
for the four serotypes; ‘monotypic’, if antibody titres were 10
(1/dil) for only one serotype or if titres were 10 (1/dil) for
S. Garg et al. / International Journal of Infectious Diseases 54 (2017) 25–30 27different serotypes, with a single serotype having a high titre (>80
(1/dil) titre, and 5 times higher than other titres); and ‘multi-
typic’, if antibody titres were 10 (1/dil) for different serotypes
without a single predominant titre.
At each site, a designated clinical research associate performed
periodic visits tomonitor implementation. All serum sampleswere
checked for quantity and storage temperature by a lot quality
assurance method.
2.5. Statistical analysis
Descriptive statistics reported baseline characteristics and
immunogenicity results. Associations between all demographic–
socio-economic factors and dengue serostatus were assessed by
univariate analysis using the Chi-square test or t-test (for age) and
multiple logistic regression with backward selection (signiﬁcant if
the p-value is 0.05). JE serostatus was not included as a covariate
due to possible cross-reaction between ﬂavivirus antibodies.
Statistical signiﬁcance was considered at and below a p-value of
0.05. Statistical analyses were performed using SAS software
version 9.1 (SAS Institute, Cary, NC, USA) and Stata v. 12.1
(StataCorp LP, College Station, TX, USA).
2.6. Role of the funding source
The sponsor participated in all operational aspects of the study,
including data collection, statistical analyses, and thewriting of the
study report. The sponsor funded medical writing support for the
development of this publication. The corresponding author had full
access to all of the data in the study and had ﬁnal responsibility for
the decision to submit for publication.
3. Results
3.1. Demographic characteristics of the study population
Overall, 2609 participants from eight health centres were
enrolled in the study. A total of 18 participants were excluded, due
to age <5 years or >10 years (n = 8) and/or assent form not signed
(n = 13). Thus, 2591 participants were included, all of whom had a
blood sample drawn; 1364 (52.6%) were female, and the mean age
of all participants was 7.8 (standard deviation (SD) 1.6) years.[(Figure_1)TD$FIG]
Figure 1. Dengue IgG ser3.2. Socio-economic characteristics
The mean number of people living in the participants’ house-
holds was 5.4 (SD 2.3), including 2.6 (SD 1.2) children under
15 years of age. Most (2170/2591; 83.8%) participants lived in a
house, with 381 (14.7%) living in precarious lodgings; 1121 (43.3%)
had an indoor piped public water supply, 2343 (90.4%) had water
storage in the house, 1675 (64.6%) were connected to the public
sewer, and 1339 (51.7%) had regular organized waste collection.
3.3. Medical history
A notable medical history was recorded for 94 (3.6%) children;
61 (2.4%) children were undergoing at least one current treatment
at the time of enrolment. A history of dengue or a family history of
dengue was reported by 15 (0.6%) and 48 (1.9%) participants,
respectively. No participants reported a history or family history of
JE infection. Only one participant reported receiving JE vaccination.
3.4. Dengue IgG seroprevalence
Anti-dengue IgG results were available for 2558/2591 (98.7%)
participants. Serology data were missing for 33 participants;
22 samples from a single site (Mumbai) could not be analysed due
to haemolysed red blood cells. Overall, 1525/2591 (59.6%)
participants were dengue seropositive, with similar prevalence
in males and females. Six of the eight sites had dengue
seropositivity ranging from 58.2% to 69.0%. The sites in Kalyani
and Mumbai had the lowest (23.2%) and highest (80.1%)
seroprevalence, respectively (Figure 1). Overall, dengue IgG
seroprevalence increased with age, from 40.7% (95% CI 36.0–
45.5%) in children aged 5 years to 73.4% (95% CI 67.9–78.5%) in 10-
year-olds (Figure 2). At the Bangalore site, seroprevalence
remained relatively stable across the age strata (varying from
58.8% in 7-year-olds to 70.9% in 8-year-old children).
3.5. Socio-economic characteristics associated with dengue
seroprevalence status
In univariate analyses, children seropositive for dengue were
found more likely to be from homes with more than two children
(p < 0.0001), more likely to have water storage (p < 0.0001) andoprevalence by site.
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Figure 2. Percentage of participants with antibody titres10 (1/dil) against dengue
according to age group (all study sites). Error bars show 95% conﬁdence intervals. n,
number of participants with available results per age group.
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less likely to be living in precarious housing (p = 0.0048) compared
with dengue seronegative children (Table 1). Multiple logistic
regression conﬁrmed possible positive associations with house-
hold water storage (odds ratio (OR) 5.00, 95% CI 3.54–7.06) and
indoor piped water from the public water supply (OR 1.49, 95% CI
1.19–1.85). Increasing participant age (p < 0.0001) and living in
precarious lodgings compared to a house (OR 1.54, 95% CI 1.17–
2.03) were also associated with dengue status. In terms of
geography, Kalyani was associated with decreased exposure (OR
0.18, 95% CI 0.10–0.31), while Wardha (OR 1.49, 95% CI 1.07–2.08)
and Mumbai (OR 2.49, 95% CI 1.70–3.65) had an elevated risk, in
comparisonwithDelhi. The pseudo R2 of the ﬁnalmodelwas 0.085.
3.6. Dengue serotype analysis
Of 1525 IgG seropositive participants tested, 1511 had PRNT50
data available for all four serotypes. Of these, 1468 (97.2%) had
antibody titres 10 for at least one serotype and 1205 (79.7%) had
antibody titres 10 against all four serotypes. Nearly half (736/
1511; 48.7%) had a multitypic antibody proﬁle and 732/1511
(48.4%) had a monotypic proﬁle. DENV-1, DENV-2, and DENV-3
were nearly equally represented among dominant serotypes in
participants with monotypic proﬁles overall (Figure 3).Table 1




Age, mean (SD) years 8.13 (1.56)
Socio-economic characteristics
Number of children living in the household (%)
2 children 855 (56.07)
>2 children 670 (43.93)
Type of housing (%)
House 1290 (84.6)
Apartment 29 (1.9)
Precarious lodgings 206 (13.5)
Water storage in the house (%) 1465 (96.1)
Indoor piped public water supply (%) 721 (47.3)
Connected to public sewer (%) 959 (62.9)
IgG, immunoglobulin G; SD, standard deviation.
a The odds ratio (in parentheses) is provided for signiﬁcant categorical multivariate
* p<0.05 in multivariate analysis.
b t-test.
c Chi-square test.3.7. Japanese encephalitis IgG seroprevalence
Anti-JE IgG results were available for 2544 (98.2%) participants.
Of these, 345 (13.6%; 95% CI 12.3–15.0%) participants were
seropositive against JE, 327 (94.8%) of whom were also dengue
seropositive (Table 2). JE seroprevalence ranged from 4.3% (95% CI
2.4–7.1%) in Kalyani to 20.5% (95% CI 16.2–25.3%) in Wardha.
4. Discussion
These ﬁndings demonstrate a high intensity of dengue
transmission among children in India; more than 50% of the
children had been infected at least once by the age of 6 years,
results which are broadly consistent with existing, limited dengue
seroprevalence data for adults and children in Chennai and
Hyderabad.10,11 All four serotypes were found to circulate, varying
by geographic location. Nearly half of all participants had a
multitypic dengue antibody proﬁle. Dengue IgG seroprevalence
increased with age at all but one study site, consistent with age-
related cumulative exposure to dengue.10 The exception in
Bangalore could be related to epidemiological, behavioural, or
environmental factors moderating exposure risk, such as the
occurrence of large, infrequent outbreaks.
The observed level of dengue exposure was comparable to that
reported in other highly endemic countries of Southeast Asia and
Latin America: 56.2% for 4–9-year-olds in Yogyakarta, Indonesia
(1995–1996),12 65% for 11-year-olds in Rayong, Thailand (2010),13
34.4% for under 7-year-olds to 70.5% in 14–16-year-olds from a
primary health care facility in Sri Lanka (2013–2014),14 53% for
under 7-year-olds and 88% by the age of 13 years among primary
school children in southern Vietnam,15 and 35.7% and 52.2% for
5–9 and 10–14 years age groups, respectively, in two localities in
Mexico in 2011.16 A higher seroprevalencewas observed in a study
in Managua, Nicaragua (2001–2003), where 80% of enrolled
children were seropositive by 5 years of age.17
Considering these similarities in exposure history, it might be
expected that rates of symptomatic, reported dengue are similar in
India and other countries. In fact, there are huge disparities: from
2007 to 2011, India reported an approximate average annual
incidence of 1.4 cases/100 000 population,5 whereas case
notiﬁcations in Cambodia, Malaysia, the Philippines, and Sri Lanka
for 2011 were 119, 70.4, 134, and 135 per 100 000, respective-
ly.18,19 Despite their signiﬁcant and often multitypic infection
history, very few participants in the present study reported a
history of dengue. Similarly low reporting was observed in thece status
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Figure 3. Proportion of participants with PRNT50 results showing monotypic proﬁles, according to dominant serotype, by site and overall.
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(93%) subjects were dengue IgG seropositive, but only 1% of
participants reported a history of dengue. The present authors are
unaware of virological or genetic factors that might disassociate
infection history from the incidence of symptomatic disease; likely
explanations include a lack of health-seeking for patients with
apparent infection, lack of recognition of the disease, or
misdiagnosis of dengue.1,4 For these reasons, and because dengue
surveillance reports are collected from only sentinel sites,3 it must
be assumed that dengue burdens reported in the routine
surveillance system represent only a fraction of symptomatic
episodes.
In the current study, serotype-speciﬁc analyses identiﬁed
historical circulation of all four dengue virus serotypes at each
site, with DENV-1 present in a high proportion of samples in New
Delhi and DENV-3 in Kalyani. These serological ﬁndings in children
are worrying: co-circulation of multiple serotypes is a population
risk factor for severe dengue because it allows for sequential
infection, and because secondary infection is a risk factor for severe
disease.20,21
Multivariate risk factor analysis suggested relationships be-
tween water availability/storage practices and dengue infection
risk, an association with biological plausibility due to the aquatic
larval and pupal stages of the vector life-cycle. However, these
results should be interpreted with caution because they were
mainly driven by data fromKalyani and are thus highly susceptibleTable 2




JE IgG n 2591 1525 1033
Positive 345 327 18
Negative 1794 801 990
JE, Japanese encephalitis; n, number of participants with results corresponding to
the speciﬁed category.
a 33/2591 total samples had no results available for dengue IgG; 47 were
inconclusive and 405 were missing for JE IgG.to confoundingwith site-speciﬁc socio-demographic covariates, or
other factors. After excluding Kalyani data from the multivariate
analysis, only participant age remained signiﬁcantly associated
with dengue positivity. Furthermore, the determination coefﬁcient
(R2) of the model was lower than 0.1, conﬁrming the limited
predictive value of these variables for dengue serostatus, in
agreement with inconclusive/variable socio-economic drivers of
dengue serostatus identiﬁed in other studies. In Chennai, univari-
ate logistic regression showed a negative association with
household income and no associations with other household
factors.10 Thai et al. (2005) found associations with littering in and
around the home and the types of sanitary facilities in an initial
univariate analysis, but these associations were not conﬁrmed on
multivariate analysis.15 A community-based study of potential risk
factors for dengue transmission in Venezuela found several
household and socio-economic factors, including storing water
and used tyres (univariate analysis), and crowding, household size,
and living in a shack (multivariate analysis), to be associated with
an increased risk of dengue infection.22
The seroprevalence of anti JE IgG antibodies was also measured
in the participants in the present study. JE is endemic in some
regions in India, particularly in the south and north-east;23
however, during the current study period, none of the study sites
were considered to be within a JE endemic area and none were in
an area subject to routine JE vaccination. The observed seropreva-
lence of JE in the current study (13.6%; 95% CI 12.3–15.0%) conﬁrms
circulation of the virus, but is lower than that reported in a number
of other studies on JE seroprevalence in endemic countries,14,24,25
perhaps because these sites are located within less-endemic areas
of India.
Cross-reaction between anti-ﬂavivirus IgG antibodies has been
documented26 and cannot be excluded here from affecting the
observed JEV or dengue IgG rates. The PRNT is amore speciﬁc assay
and may be used to distinguish between cross-reactive and
pathogen-speciﬁc responses. Encouragingly, 99% of dengue IgG-
positive samples in the current study were also dengue PRNT-
positive. However, the lack of JEV PRNT data and dengue PRNT in
dengue-negative samples remains a limitation in conclusively
addressing this risk.
S. Garg et al. / International Journal of Infectious Diseases 54 (2017) 25–3030Other limitations include the use of different dengue-speciﬁc
IgG ELISAs at different sites, but the sensitivity test showing 100%
concordance was reassuring. In this study, a convenience sample
was selected, including some low-income settings, to provide
geographical spread across India. However, sites were not
randomly selected, subjects were consecutively recruited, and
these data cannot be considered nationally or locally representa-
tive. As with other epidemiological studies, recall bias (during the
questionnaire) and selection bias (e.g., self-selection of healthy
subjects) cannot be excluded. Despite these sampling limitations,
these data provide a ﬁrst multi-centre view on dengue seropreva-
lence in India. The use of a single protocol and consistent methods
between the sites strengthens the validity of the data.
In conclusion, high levels of dengue exposure were observed in
Indian children, and age-stratiﬁed data describe transmission
intensity at these locations. This information may inform dengue
burden estimates and populate transmission models to assess the
potential impact of prevention and control measures, including
vaccination programmes.
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